Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05878691 · ClinicalTrials.gov registry record · Phase 1
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
A Phase 1 study of Lymphoma and Advanced Solid Tumor, sponsored by Glenmark Specialty S.A..
- Active
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 18
- Study locations
NCT05878691 is a Phase 1 study of Lymphoma and Advanced Solid Tumor that is active but no longer recruiting, run by Glenmark Specialty S.A.. The registered enrollment target is 320 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (34% lower). The trial reports 18 study locations across 9 states.
The verdict
NCT05878691, a Phase 1 study of Lymphoma and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Glenmark Specialty S.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D), and c) pharmacokinetic profile of GRC54276 alone and in combination with pembrolizumab or atezolizumab in participants with advanced solid tumors and lymphomas.
Conditions Studied
Interventions
- DRUG GRC 54276
- DRUG GRC 54276 + Pembrolizumab
- DRUG GRC 54276 + Atezolizumab
Study Locations (18)
Maharashtra
- Krupamayi Hospitals - Aurangabad
- PD Hinduja Hospital and Medical Research Centre - Mumbai
- HCG Manavata Cancer Centre - Nashik
- Sankalp Hospital - Nashik
- Bhaktivedanta Hospital and Research Institute - Thane
Karnataka
- Health Care Global Enterprises Ltd (HCG) - Bangalore
- Vydehi Hospital - Bangalore
- Cytecare Hospitals Pvt Ltd. - Bengaluru
- Aster CMI Hospital - Bengaluru
Andhra Pradesh
- Hcg City Cancer Centre - Vijayawada
- Mahatma Gandhi Cancer Hospital and Research Institute - Visakhapatnam
Telangana
- AIG Hospitals, (A unit of asian Institute of Gastroenterology) - Hyderabad
- Basavatarakam Indo American Cancer Hospital Research Institute - Hyderabad
North Carolina
- Carolina BioOncology Institute - Huntersville
Wisconsin
- Froedtert & Medical College of Wisconsin - Froedtert Hospital - Clinical Cancer Center - Milwaukee
Haryana
- Artemis Hospital - Gurgaon
Kerala
- Malabar Cancer Centre - Kannur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05878691
The ClinicalTrials.gov registry entry for NCT05878691 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (34% lower). The listed sponsor is Glenmark Specialty S.A., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which GRC 54276 is the first listed.
NCT05878691 reports 18 study locations spanning 9 distinct geographic areas - top geographies include Maharashtra, Karnataka, Andhra Pradesh.
Frequently Asked Questions
What is clinical trial NCT05878691 about?
NCT05878691 is a clinical study titled "A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.". This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D), and c) pharmacokinetic profile of GRC54276 alone and in combination with pembrolizumab or atezolizumab in participant...
What is the current status of trial NCT05878691?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2022-06-28. Estimated completion is 2027-07-30.
What conditions does trial NCT05878691 study?
This clinical trial studies the following conditions: Lymphoma, Advanced Solid Tumor.
What interventions are being tested in trial NCT05878691?
The interventions under investigation include: GRC 54276 (DRUG), GRC 54276 + Pembrolizumab (DRUG), GRC 54276 + Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT05878691?
This trial is sponsored by Glenmark Specialty S.A., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05878691 being conducted?
This trial has 18 study locations across North Carolina, Wisconsin, Andhra Pradesh, Haryana, Karnataka. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.